<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01105143</url>
  </required_header>
  <id_info>
    <org_study_id>EA 20100415</org_study_id>
    <nct_id>NCT01105143</nct_id>
  </id_info>
  <brief_title>Effects of Negative Energy Balance on Muscle Mass Regulation</brief_title>
  <official_title>Effects of Negative Energy Balance on Muscle Mass Regulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators here propose to perform a prospective randomized intervention trial in
      post-menopausal women to investigate the endocrine network, which contributes to the changes
      in skeletal muscle mass during weight loss.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2012</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of myocellular insulin sensitivity (hyperinsulinemic clamp) during negative energy balance and during stabilized modification of body composition after weight loss.</measure>
    <time_frame>4 months</time_frame>
    <description>Analysis of myocellular insulin sensitivity by hyperinsulinemic clamp in mg•kg−1•min−1/(mU•L−1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of skeletal muscle mass (air displacement plethysmography) during negative energy balance and during stabilized modification of body composition after weight loss.</measure>
    <time_frame>4 months</time_frame>
    <description>Analysis of muscle mass (in % of body weight)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects on energy expenditure</measure>
    <time_frame>4 months</time_frame>
    <description>Measurement of energy expenditure (kcal/d), postprandial thermogenesis (%) and respiratory coefficient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on myocellular and adipose tissue metabolism and substrate utilization</measure>
    <time_frame>4 months</time_frame>
    <description>Measurement of myocellular and adipose metabolism using microdialysis (glycerol (µmol/l), lactate (mmol/l), pyruvate (µmol/l), glucose (mmol/l)) during oral glucose load (180 minutes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on myocellular and adipose tissue mRNA expression</measure>
    <time_frame>4 months</time_frame>
    <description>Analysis of myocellular and adipose mRNA expression (RNA sequencing) in counts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight regain</measure>
    <time_frame>24 months</time_frame>
    <description>Analysis of body weight regain (BMI; kg/m2) during follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat mass</measure>
    <time_frame>24 months</time_frame>
    <description>Analysis of body fat (kg and %)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of human gut microbiome at baseline, during weight loos, after weight loss (negative energy balance) and during stabilized modification of body composition 4 weeks after weight loss</measure>
    <time_frame>4 months</time_frame>
    <description>16S rRNA sequencing and/or shotgun metagenomic pyrosequencing of the gut microbiota for assessment of microbiota composition and gene abundances.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>FFA during negative energy balance and during stabilized modification of body composition after weight loss.</measure>
    <time_frame>12 months</time_frame>
    <description>Measurement of fatty acids at baseline, during negative energy balance, during stabilized modification of body composition after weight loss and during follow up.</description>
  </other_outcome>
  <other_outcome>
    <measure>Metanephrines during negative energy balance and during stabilized modification of body composition after weight loss.</measure>
    <time_frame>12 months</time_frame>
    <description>Measurement of metanephrines at baseline, during negative energy balance, during stabilized modification of body composition after weight loss and during follow up.</description>
  </other_outcome>
  <other_outcome>
    <measure>Leptin during negative energy balance and during stabilized modification of body composition after weight loss.</measure>
    <time_frame>12 months</time_frame>
    <description>Measurement of leptin at baseline, during negative energy balance, during stabilized modification of body composition after weight loss and during follow up.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cortisol during negative energy balance and during stabilized modification of body composition after weight loss.</measure>
    <time_frame>12 months</time_frame>
    <description>Measurement of cortisol at baseline, during negative energy balance, during stabilized modification of body composition after weight loss and during follow up.</description>
  </other_outcome>
  <other_outcome>
    <measure>Follistatin during negative energy balance and during stabilized modification of body composition after weight loss.</measure>
    <time_frame>12 months</time_frame>
    <description>Measurement of follistatin at baseline, during negative energy balance, during stabilized modification of body composition after weight loss and during follow up.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adiponectin during negative energy balance and during stabilized modification of body composition after weight loss.</measure>
    <time_frame>12 months</time_frame>
    <description>Measurement adiponectin at baseline, during negative energy balance, during stabilized modification of body composition after weight loss and during follow up.</description>
  </other_outcome>
  <other_outcome>
    <measure>Natriuretic peptide during negative energy balance and during stabilized modification of body composition after weight loss.</measure>
    <time_frame>12 months</time_frame>
    <description>Measurement of natriuretic peptide at baseline, during negative energy balance, during stabilized modification of body composition after weight loss and during follow up.</description>
  </other_outcome>
  <other_outcome>
    <measure>IGF-1 during negative energy balance and during stabilized modification of body composition after weight loss.</measure>
    <time_frame>12 months</time_frame>
    <description>Measurement of IGF-1 at baseline, during negative energy balance, during stabilized modification of body composition after weight loss and during follow up.</description>
  </other_outcome>
  <other_outcome>
    <measure>Analysis of predictive impact of several hormonal and metabolic parameters on body weight regain, course of insulin sensitivity and metabolism</measure>
    <time_frame>24 months</time_frame>
    <description>The effect of measured parameters (see other endpoints) on long-term course of BMI, muscle mass, insulin sensitivity and energy expenditure will be analyzed using mathematical models</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Weight Loss</condition>
  <condition>Obesity</condition>
  <condition>Skeletal Muscle</condition>
  <condition>Insulin Sensitivity/Resistance</condition>
  <arm_group>
    <arm_group_label>lifestyle intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Multimodal lifestyle intervention to reduce body weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>multimodal lifestyle intervention</intervention_name>
    <description>multimodal lifestyle intervention will be performed to reduce body weight</description>
    <arm_group_label>lifestyle intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>no intervention, only follow up</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI &gt; 27 kg/m2 (adults)

          -  postmenopausal state

        Exclusion criteria:

          -  weight loss of more than 5kg in the last 2 months x

          -  unhealthy patients with: severe chronic diseases including cancer within the last 5
             years, severe heart disease, severe impairment of hepatic or renal function, severe
             anaemia or disturbed coagulation

          -  eating disorders or any other psychiatric condition that would interact with the trial
             intervention

          -  malabsorption

          -  acute or chronic infections

          -  severe hypertension

          -  myopathy

          -  food allergies

          -  any other uncontrolled endocrine disorder

          -  changes of smoking habits, diets or medication that strongly affects energy
             homeostasis within the last 3 months prior to study inclusion
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Knut Mai, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charite</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2010</study_first_submitted>
  <study_first_submitted_qc>April 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2010</study_first_posted>
  <last_update_submitted>December 18, 2017</last_update_submitted>
  <last_update_submitted_qc>December 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Professor Joachim Spranger</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>weight loss</keyword>
  <keyword>muscle mass</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Weight Loss</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

